Eyeworld

3 EW ASCRS NEWS March 2019 Redesigns are complicated. But we had a cohesive team with a clear understanding of EyeWorld readers and in-depth knowledge of the pub- lication inside and out. We accepted the challenge and got to work. Redesign EyeWorld's graphic designers started immediately experimenting with new logos and looks, and the re- search portion of the team launched a readership survey to see what read- ers thought of the magazine. The survey showed that readers found EyeWorld to be both credible and relevant to their work. Also, they overwhelmingly liked the clinical content, though it was clear they'd welcome somewhat shorter stories and more visuals like charts and infographics. These survey results and other conversations with readers and ASCRS leadership, combined with our team's expertise in content creation, production, and design, in- formed our brainstorms, discussions, and decisions. Through countless conversations and emails, we made steady progress on the redesign. We updated Mr. Speares regularly, and met with EyeWorld's chief medical editor and the ASCRS Executive Committee for their feedback. After several months of hard but exciting work, we can officially say we will bring you the new, updated look of EyeWorld in our next issue, the ASCRS•ASOA Annual Meeting show issue, which will be mailed in April and distributed onsite in San Diego. Next month, you'll find a new logo, cover art, inner design, size, and article length with the knowl- edgeable sources, balanced report- ing, clinical focus, ASCRS news, and care and attention to all parts of the magazine that you've come to expect of this award-winning publication. I hope you'll join us in celebrat- ing our more than 20-year history with a retrospective look at past In the April issue, EyeWorld will unveil a new look while continuing solid reporting on clinical issues at the heart of ophthalmology Publishing profession Current trends, technologies, and resources continually provide the world of publishing with opportu- nities for creativity and innovation. The key to facing any publishing challenge is striking a balance be- tween tradition—what you've been doing—and innovation—what you could be doing. What works? What needs to change? How do we address new technologies? How do we meet our readers' needs? The foundational challenge is answering these ques- tions while keeping the publication on track. In responding to these issues, a publication should stay attentive to the various needs of the read- ers, contributors, sources, editorial board, advertisers, staff, and in the case of niche publications like EyeWorld, the society that owns it. No publication can be everything to everyone, but each should work to facilitate communication among the contributors and audience. EyeWorld EyeWorld launched in October 1996 as the news magazine of ASCRS, and it's been going strong ever since. It covers the world of ophthalmology, helping anterior segment surgeons share their experiences and exper- tise. While maintaining the monthly magazine, EyeWorld later expanded its digital options and events as technology and audiences chal- lenged us to do more. A few months after Steve Speares took the helm as the new executive director of ASCRS, he thought that the magazine was ready for a refreshed look and feel. Was the EyeWorld team up for a redesign? by Amy Goldenberg EyeWorld Editorial Director Journey to a redesign: Innovating while keeping with tradition Contact information Goldenberg: amy@eyeworld.org covers on the last page of this issue as we look forward to unveiling the new design to you next month. EW © 2019 Novartis 1/19 US-ORA-18-E-2623a ORA SYSTEM ® Technology - IMPORTANT PRODUCT INFORMATION CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician. INDICATIONS: Federal (USA) law restricts this device to sale by, or on the order of, a physician. INTENDED USE: The ORA SYSTEM ® technology utilizes wavefront aberrometry data to measure and analyze the refractive power of the eye (i.e. sphere, cylinder, and axis measurements) to support cataract surgical procedures. WARNINGS AND PRECAUTIONS: The following conditions may make it difficult to obtain accurate readings using the ORA SYSTEM ® technology: • Patients having progressive retinal pathology such as diabetic retinopathy, macular degeneration, or any other pathology that the physician deems would interfere with patient fixation; • Patients having corneal pathology such as Fuchs', EBMD, keratoconus, advanced pterygium impairing the cornea, or any other pathology that the physician deems would interfere with the measurement process; • Patients for which the preoperative regimen includes residual viscous substances left on the corneal surface such as lidocaine gel or viscoelastics; • Visually significant media opacity, such as prominent floaters or asteroid hyalosis, will either limit or prohibit the measurement process; or • Patients having received retro or peribulbar block or any other treatment that impairs their ability to visualize the fixation light. • Use of iris hooks during an ORA SYSTEM ® technology image capture will yield inaccurate measurements. In addition: • Significant central corneal irregularities resulting in higher order aberrations might yield inaccurate refractive measurements. • Post refractive keratectomy eyes might yield inaccurate refractive measurement. • The safety and effectiveness of using the data from the ORA SYSTEM ® have not been established for determining treatments involving higher order aberrations of the eye such as coma and spherical aberrations. • ORA SYSTEM ® technology is intended for use by qualified health personnel only. • Improper use of this device may result in exposure to dangerous voltage or hazardous laser-like radiation exposure. DO NOT OPERATE the ORA SYSTEM ® in the presence of flammable anesthetics or volatile solvents such as alcohol or benzene, or in locations that present an explosion hazard. ATTENTION: Refer to the ORA SYSTEM ® Operator's Manual for a complete description of proper use and maintenance, as well as a complete list of contraindications, warnings and precautions. IT'SABRANDNEWDAYAT COMING APRIL 2019

• Blank Page
• Blank Page (1)